{"filings":[{"id":99601,"accession_number":"0000899923-26-000036","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q1 revenue $200.4M, GAAP net loss $34.1M; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $34.1M ($0.36/sh); adjusted loss $0.09/sh; adjusted EBITDA negative $4.5M.","Revenue $200.4M (+2% YoY); Cancer Care +4%, Prenatal -15%, Mental Health +24%.","Test volumes 385k flat YoY; Cancer Care +13%, Prenatal -12%, Mental Health +7%.","Launched Precise MRD (ultrasensitive assay) and received FDA approval for MyChoice CDx as Zejula companion diagnostic.","Reiterated FY 2026 guidance: revenue $860-880M, adjusted EBITDA $37-49M, adj. gross margin 68-69%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":200400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115701,"accession_number":"0000899923-26-000012","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q4 2025 revenue $209.8M, net loss $7.9M; reiterates 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $7.9M ($0.08 loss per share); adjusted EPS $0.04.","Revenue $209.8M roughly flat YoY; hereditary cancer testing volume +9%, GeneSight +9%, prenatal -6%.","Full-year 2025 revenue $824.5M down 2%; reiterates 2026 revenue guidance $860-880M.","Adjusted EBITDA $14.3M in Q4; company expects 2026 adjusted EBITDA $37-49M.","Plans to launch Precise MRD in March 2026, AI-enabled Prolaris in Q2 2026, FirstGene in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":824500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115700,"accession_number":"0000899923-26-000003","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics prelim Q4 revenue $207-209M, FY25 $822-824M; FY26 guidance $860-880M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 total revenue $207-209M; full year 2025 revenue $822-824M.","Full year 2025 test volumes ~1.5M (+1% YoY): hereditary cancer +7%, mental health +6%, prenatal -4%.","FY 2026 revenue guidance $860-880M (midpoint +6% vs FY25 prelim midpoint).","FY 2026 adjusted gross margin guidance 68-69%; adjusted EBITDA $37-49M (midpoint +43% vs prior FY25 guide).","Formal Q4/FY 2025 earnings call scheduled for February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":824500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132131,"accession_number":"0000899923-25-000109","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K/A","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q3 revenue $205.7M (-4% YoY); adjusted EPS $0.00; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M headwinds (UNH GeneSight loss, EndoPredict divestiture).","GAAP net loss $27.4M ($0.29 loss); adjusted EPS $0.00; adjusted EBITDA $10.3M.","Hereditary cancer testing volume +11% YoY; GeneSight revenue -19% YoY due to UnitedHealthcare coverage change.","Entered strategic CDx collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics.","Reiterates FY2025 revenue $818-828M, gross margin 69.5-70%, adjusted EBITDA $27-33M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":614700000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132134,"accession_number":"0000899923-25-000103","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q3 revenue $205.7M (-4% YoY); GAAP net loss $0.29/sh, adj EPS $0.00; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M in headwinds from UNH GeneSight coverage loss and EndoPredict divestiture.","GAAP net loss $27.4M ($0.29 per share); adjusted EPS $0.00; adjusted EBITDA $10.3M.","Hereditary cancer testing volume +11% YoY, revenue +3%; pharmacogenomics revenue -19% due to UnitedHealthcare coverage discontinuation.","Gross margin 69.9%; cash and equivalents $145.4M as of Sept 30, 2025.","Entered strategic collaboration with SOPHiA GENETICS for global liquid biopsy companion diagnostic development."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":614700000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132133,"accession_number":"0000899923-25-000096","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myriad Genetics finalizes separation agreement with former CFO Scott Leffler; $1.24M severance plus equity acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott J. Leffler's separation effective Sep 2, 2025; lump-sum severance payment of $1,239,384.","Unvested time-based equity awards scheduled to vest within 2 years accelerated; performance-based awards remain outstanding.","COBRA medical premiums paid by company for up to one year after separation date.","Leffler reaffirms non-compete, non-solicitation, and non-disparagement obligations.","Company provides neutral references; no admission of liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132132,"accession_number":"0000899923-25-000091","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Myriad Genetics principal accounting officer Natalie Munk to resign; CFO Wheeler to assume role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Natalie Munk resigns as SVP, Chief Accounting Officer and principal accounting officer; effective October 24, 2025.","Departure is not due to any disagreement with the Company on operations, policies, or practices.","CFO Benjamin R. Wheeler designated as principal accounting officer effective on Munk's departure date.","Wheeler, 42, has been with Myriad for 13 years, including CFO since August 2025, and holds a CPA from BYU.","Wheeler will not receive any additional compensation for the additional role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148702,"accession_number":"0000899923-25-000089","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myriad Genetics appoints Ben Wheeler as CFO; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Leffler stepped down as CFO effective Aug 15, 2025; will consult through Sept 2, 2025.","Ben Wheeler appointed CFO effective Aug 16, 2025; previously SVP, CFO of Operations for 13 years.","Wheeler receives $490,000 base salary, 75% bonus target, and 120,000 RSUs (60k time, 60k performance).","Full-year 2025 financial guidance reaffirmed as announced on Aug 5, 2025 Q2 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148701,"accession_number":"0000899923-25-000084","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.","Hereditary cancer testing revenue +9% YoY in Oncology; MyRisk with RiskScore volume +14%.","Raised 2025 revenue guidance to $818-828M from $807-823M; adjusted EPS reiterated at $(0.02)-$0.02.","New $200M credit facility with OrbiMed entered July 31; plans to launch ultra-sensitive MRD test H1 2026.","GeneSight revenue down 12% due to UHC coverage discontinuation; prenatal revenue +7%."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":409000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148700,"accession_number":"0000899923-25-000072","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Myriad Genetics closes $200M credit facility with OrbiMed; $125M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year senior secured term loan; $125M funded at closing, $75M delayed draw available through June 2027.","Interest rate of one-month SOFR + 6.50%, with a 2.50% SOFR floor; matures July 31, 2030.","Proceeds for working capital, general corporate purposes, and refinancing existing ABL facility.","Credit facility is secured by substantially all assets of Myriad and its subsidiaries.","Company now has access to over $200M in capital (including cash) to support growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167579,"accession_number":"0000899923-25-000066","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Myriad shareholders approve 6.5M share increase to 2017 equity plan; per-participant cap raised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2017 Plan adding 6.5 million shares for equity grants.","Board increased annual per-participant share cap from 500,000 to 574,040 shares.","All three director nominees (Raha, Dreismann, Reitan) elected with >97% of votes cast.","Advisory say-on-pay approved with 92% of votes cast in favor.","Ernst & Young ratified as auditor for fiscal 2025 with 95.6% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167578,"accession_number":"0000899923-25-000045","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q1 revenue down 3% to $196M; net loss of $0.1M; lowers FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $0.1M ($0.00 EPS); adjusted EPS $(0.03). Revenue of $196M declined 3% YoY.","Prenatal revenue grew 11% YoY; Pharmacogenomics revenue fell 20% due to UnitedHealthcare coverage cut for GeneSight.","Gross margin 69% (+40 bps YoY) on lab efficiencies; operating loss $29M vs $27.9M YoY.","Updated FY2025 revenue guidance lowered to $807-823M from $840-860M; adjusted EPS now $(0.02)-$0.02.","CEO cited challenges in GeneSight and unaffected hereditary cancer; taking steps to reduce costs and drive growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":195900000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184864,"accession_number":"0000899923-25-000010","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Myriad Genetics: CEO succession plan; Q4 revenue $211M (+7%), FY 2024 revenue $838M (+11%)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Paul J. Diaz resigns effective April 30, 2025; COO Samraat S. Raha appointed President, CEO, and Board member.","Mark S. Verratti promoted to COO effective April 30, succeeding Raha.","Q4 2024 revenue $211M (+7% YoY); full-year revenue $838M (+11% YoY). GAAP net loss $43M (Q4) and $127M (FY).","Adjusted EBITDA Q4 $11M, FY $40M; 2025 guidance reaffirmed: revenue $840-$860M, adjusted EPS $0.07-$0.11.","Exclusive license of PATHOMIQ AI platform for prostate cancer; commercial launch planned later in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184863,"accession_number":"0000899923-25-000002","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics reports preliminary Q4 rev $209-211M, FY2025 adj EPS guidance $0.07-0.11","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 preliminary revenue $209-211M (+6-7% YoY); GAAP diluted loss $(0.72)-(0.62)/share; adj EPS $0.03-$0.04.","Full year 2024 preliminary revenue $836-838M (+11% YoY); GAAP loss $(1.66)-(1.56)/share; adj EPS $0.14-$0.15.","Cash and equivalents $102M as of Dec 31, 2024, up $2M from Q3.","FY2025 guidance: revenue $840-860M (0-3% growth); adj EPS $0.07-$0.11; adj EBITDA $25-35M.","FY2025 guidance reflects impact from UnitedHealthcare coverage changes and EndoPredict divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":837600000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201459,"accession_number":"0000899923-24-000065","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myriad Genetics appoints Mark S. Davis to Board, expanding to nine members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark S. Davis appointed as Class I Director effective December 10, 2024, expanding Board from eight to nine.","Davis will serve on Audit and Finance Committee; deemed independent and an audit committee financial expert.","Received restricted stock unit award of $350,000 vesting one year from grant date.","Davis spent nearly 40 years at Deloitte & Touche LLP, last as National Managing Partner of Deloitte Private.","Also serves on boards of Yext, Inc., NYU-Winthrop Hospital, and Adelphi University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201458,"accession_number":"0000899923-24-000060","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Myriad Genetics derivative lawsuit settled; court approves $950k fee award, dismisses claims with prejudice","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court approves global settlement of shareholder derivative litigation; no admission of liability.","Company pays $950,000 in attorneys' fees and expenses; adopts corporate governance reforms.","Consolidated Delaware derivative actions and federal derivative action dismissed with prejudice.","Settlement relates to complaints alleging fiduciary duty breaches by former and current directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201457,"accession_number":"0000899923-24-000054","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q3 revenue +11% to $213M, adj EPS $0.06; UNH to drop GeneSight coverage Jan 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $213M (+11% YoY); GAAP net loss $22.1M improved from $61.3M loss; adj EBITDA $14.1M vs $1.4M.","GAAP EPS -$0.24 vs -$0.75; adj EPS $0.06 vs -$0.03.","FY2024 guidance raised: revenue $837-843M, adj EPS $0.12-0.14.","UnitedHealthcare to stop covering GeneSight for commercial plans Jan 1, 2025; $10M Q3 / $40M TTM revenue at risk from UNH commercial.","GeneSight revenue +34% YoY to $47.7M; total test volumes +6% to 376K."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":627000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201456,"accession_number":"0000899923-24-000048","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics expects Q3 2024 revenue of $210-212M, reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 2024 revenue expected between $210M and $212M.","Full-year 2024 revenue guidance reaffirmed at $835M-$845M.","Divestiture of EndoPredict business in Europe closed on August 1, 2024.","Results are preliminary and unaudited; subject to finalization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":627000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217459,"accession_number":"0000899923-24-000045","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Myriad Genetics discontinues part two of GeneSight study; control group deemed unreliable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part one (April 2024) showed 29% drop in all-cause hospitalizations and 39% drop in psychiatric-related hospitalizations 180 days post-GeneSight.","Part two aimed to compare GeneSight patients vs. matched non-GeneSight control; significant baseline disparities made control group non-viable.","Company concluded data comparing the two groups were not reliable and halted the analysis.","GeneSight's causal role in hospitalization reduction remains unconfirmed without a valid control group.","Company plans to publish full part one results in the near future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217458,"accession_number":"0000899923-24-000036","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q2 revenue $212M (+15% YoY); raises FY2024 guidance, adjusted EPS $0.05","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $212M (+15% YoY); GAAP EPS $(0.41) vs $(1.42) YoY; adjusted EPS $0.05 vs $(0.08).","Raises FY2024 revenue guidance to $835-$845M (11-12% growth); adj EPS to $0.08-$0.12.","Prenatal rev +25%, Pharmacogenomics +22%, Hereditary Cancer +19%; Tumor profiling -9% YoY.","Cross-license with Personalis (PSNL) for MRD patents; GSK collaboration for HRD testing.","Long-term revenue growth target raised to 12% from prior; total test volume +9% to 389K."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":413700000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237335,"accession_number":"0000899923-24-000028","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Myriad Genetics stockholders elect two directors, ratify auditor, approve advisory compensation vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["S. Louise Phanstiel and Daniel M. Skovronsky elected as directors for terms expiring 2027.","Ernst & Young ratified as independent auditor for FY 2024 with 81.5M votes for, 2.9M against.","Advisory vote on executive compensation approved with 74.4M for, 4.1M against.","Approximately 93% of outstanding shares present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237334,"accession_number":"0000899923-24-000027","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Myriad Genetics settles shareholder derivative suit; pays up to $950k in fees, adopts governance reforms","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves claims that officers misled investors about GeneSight efficacy and study compliance.","Myriad will adopt new disclosure committee charter, CCO job profiles, and amendments to several board committee charters.","Plaintiffs' counsel may seek up to $950,000 in attorneys' fees and costs, paid by Myriad or its insurers.","Court hearing on proposed settlement scheduled for August 6, 2024; defendants deny wrongdoing.","Governance reforms to remain in effect for at least four years from adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237333,"accession_number":"0000899923-24-000025","cik":899923,"company_name":"MYRIAD GENETICS INC","ticker":"MYGN","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myriad Genetics Q1 revenue $202M (+12% YoY), positive adjusted EBITDA $4M, reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $202.2M (+12% YoY); GAAP net loss narrowed to $26M from $55M.","Adjusted EPS -$0.01 vs -$0.21 YoY; positive adjusted EBITDA $4M vs -$19M.","Revenue growth driven by Prenatal (+22%), Pharmacogenomics (+21%), Hereditary Cancer (+16%).","Announced sale of EndoPredict to Eurobio Scientific; retains U.S. license.","Reiterates FY2024 guidance: revenue $820-840M, adjusted EBITDA $20-30M, adjusted EPS $0.00-$0.05."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":202200000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371181462.748052,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}